<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR46">
 <label>46.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Davidson</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>McCabe</surname>
    <given-names>TM</given-names>
   </name>
   <name>
    <surname>Crotta</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Gad</surname>
    <given-names>HH</given-names>
   </name>
   <name>
    <surname>Hessel</surname>
    <given-names>EM</given-names>
   </name>
   <name>
    <surname>Beinke</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment</article-title>
  <source>EMBO Mol Med</source>
  <year>2016</year>
  <volume>8</volume>
  <issue>9</issue>
  <fpage>1099</fpage>
  <lpage>1112</lpage>
  <?supplied-pmid 27520969?>
  <pub-id pub-id-type="pmid">27520969</pub-id>
 </element-citation>
</ref>
